Sorted By Test Name - Mayo Medical Laboratories

CTCB
89089
CTCC
89162
This test was developed and its performance characteristics
determined by IMMCO. It has not been cleared or approved by
the U.S. Food and Drug Administration.
Test Performed By: IMMCO Diagnostics, Inc.
60 Pineview Drive
Buffalo, NY 14228
Circulating Tumor Cells (CTC) for Breast Cancer by CellSearch,
Blood
Clinical Information: In patients with metastatic cancer, tumor cells may be present in the
bloodstream (circulating tumor cells [CTCs]). Studies suggest that the number of CTCs is associated with
progression-free and overall survival in patients with metastatic breast cancer.(1,2) Serial testing for
CTCs, in conjunction with other clinical methods for monitoring breast cancer, can assist physicians in
the management of these patients.(3)
Useful For: As an aid in monitoring patients with metastatic breast cancer
Interpretation: Results are reported as negative or positive. In patients with metastatic breast cancer,
positive results (> or =5 circulating tumor cells/7.5 mL of blood) are predictive of shorter progression-free
survival and shorter overall survival.(1)
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Cristofanilli M, Budd GT, Ellis MJ, et al: Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-791 2. Allard WJ,
Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in
healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004 Oct 15;10:6897-6904 3.
Cristofanilli M, Hayes DF, Budd GT, et al: Circulating tumor cells: a novel prognostic factor for newly
diagnosed metastatic breast cancer. J Clin Oncol 2006 Mar 1;23:1420-1430
Circulating Tumor Cells (CTC) for Colorectal Cancer by
CellSearch, Blood
Clinical Information: According to the American Cancer Society, colorectal cancer claims
approximately 50,000 lives each year, the vast majority of which are a result of metastatic disease.
Although there are many options for the treatment of metastatic colorectal cancer, oncologists often have
to wait several months before they can determine if a specific treatment is beneficial to the patient. The
CellSearch System identifies and enumerates the number of circulating tumor cells (CTCs) in a blood
specimen.(1) Studies suggest that the number of CTCs is associated with progression-free and overall
survival in patients with metastatic colorectal cancer.(2,3)
Useful For: An aid in the monitoring of patients with metastatic colon cancer
Interpretation: In patients with metastatic colon cancer, the finding of > or =3 circulating tumor
cells/7.5 mL of blood is predictive of shorter progression-free survival and overall survival.(2)
Reference Values:
An interpretive report will be provided.
Clinical References: 1. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the
peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant
diseases. Clin Cancer Res 2004 Oct;10:6897-6904 2. Cohen SJ, Punt CJ, Iannotti N, et al: Relationship of
circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 474